Dr Laura Cleghorn

Laura is the Tuberculosis Portfolio Leader in the Dundee Drug Discovery Unit (DDU) where she leads a team of multi-disciplinary researchers focussed on identifying novel inhibitors with the potential to be progressed toward pre-clinical candidate selection and evaluated as a new therapy for TB.

The research in Laura’s group spans the drug discovery pipeline from identifying and progressing novel screening hits through to late-stage optimisation towards pre-clinical leads and ultimately new therapeutics. Multiple strategies are employed to achieve the goal of identifying molecules targeting new pathways or those exhibiting improved profiles against a known mechanism of action. This is a highly collaborative research program where the work is coordinated with an international network of collaborators to maximise impact.